NL301256I2 - cedazuridine, of een farmaceutisch aanvaardbaar zout daarvan - Google Patents

cedazuridine, of een farmaceutisch aanvaardbaar zout daarvan

Info

Publication number: NL301256I2
Authority: NL; Netherlands
Prior art keywords: cedazuridine; pharmaceutically acceptable; acceptable salt; salt; pharmaceutically
Prior art date: 2007-10-16

Application number

NL301256C

Other languages

English (en)

Other versions

NL301256I1 (nl

Original Assignee

Otsuka Pharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-16

Filing date

2023-12-27

Publication date

2024-01-11

2023-12-27 Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd

2024-01-03 Publication of NL301256I1 publication Critical patent/NL301256I1/nl

2024-01-11 Publication of NL301256I2 publication Critical patent/NL301256I2/nl

Links

VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 title 1
229940063170 cedazuridine Drugs 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

NL301256C 2007-10-16 2023-12-27 cedazuridine, of een farmaceutisch aanvaardbaar zout daarvan NL301256I2 (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US98039707P	2007-10-16	2007-10-16
PCT/US2008/080163 WO2009052287A1 (en)	2007-10-16	2008-10-16	2 ' -flu0r0-2 ' -deoxytetrahydrouridines as cytidine deaminase inhibitors

Publications (2)

Publication Number	Publication Date
NL301256I1 NL301256I1 (nl)	2024-01-03
NL301256I2 true NL301256I2 (nl)	2024-01-11

Family

ID=40251685

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL301256C NL301256I2 (nl)	2007-10-16	2023-12-27	cedazuridine, of een farmaceutisch aanvaardbaar zout daarvan

Country Status (39)

Country	Link
US (4)	US8268800B2 (nl)
EP (2)	EP2447272B1 (nl)
JP (2)	JP5496899B2 (nl)
KR (1)	KR101543049B1 (nl)
CN (1)	CN101827856B (nl)
AT (1)	ATE548374T1 (nl)
BR (1)	BRPI0818672B8 (nl)
CA (1)	CA2702274C (nl)
CO (1)	CO6270330A2 (nl)
CR (1)	CR11427A (nl)
CY (1)	CY1112781T1 (nl)
DK (1)	DK2207786T3 (nl)
EA (1)	EA018757B1 (nl)
EC (1)	ECSP10010095A (nl)
ES (2)	ES2384011T3 (nl)
FI (2)	FIC20230040I1 (nl)
FR (2)	FR23C1051I1 (nl)
GT (1)	GT201000088A (nl)
HK (1)	HK1146410A1 (nl)
HR (1)	HRP20120419T1 (nl)
HU (2)	HUS2300044I1 (nl)
IL (1)	IL204732A (nl)
JO (1)	JO2778B1 (nl)
ME (1)	ME00997B (nl)
MX (1)	MX2010004109A (nl)
MY (1)	MY147970A (nl)
NI (1)	NI201000055A (nl)
NL (1)	NL301256I2 (nl)
NO (2)	NO2023048I1 (nl)
NZ (1)	NZ584229A (nl)
PL (1)	PL2207786T3 (nl)
PT (1)	PT2207786E (nl)
RS (1)	RS52323B (nl)
SA (1)	SA08290661B1 (nl)
SI (1)	SI2207786T1 (nl)
TW (1)	TWI445539B (nl)
UA (1)	UA99476C2 (nl)
WO (1)	WO2009052287A1 (nl)
ZA (1)	ZA201002178B (nl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11116782B2 (en)	2002-10-15	2021-09-14	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404716B2 (en)	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7964580B2 (en) *	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
JO2778B1 (en)	2007-10-16	2014-03-15	ايساي انك	Certain vehicles, installations and methods
PL3782612T3 (pl)	2008-05-15	2024-03-04	Celgene Corporation	Doustne formulacje analogów cytydyny i sposoby ich zastosowania
US8173621B2 (en)	2008-06-11	2012-05-08	Gilead Pharmasset Llc	Nucleoside cyclicphosphates
US20100055047A1 (en) *	2008-08-26	2010-03-04	Yiyu Zou	Methods for treating bronchial premalignancy and lung cancer
EA019295B1 (ru) *	2008-12-23	2014-02-28	Джилид Фармассет, Ллс.	Соединения пуриновых нуклеозидов и способ их получения
ES2628580T3 (es) *	2009-04-06	2017-08-03	Otsuka Pharmaceutical Co., Ltd.	Combinación de decitabina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer el tratamiento de cáncer
JO3197B1 (ar) *	2009-04-06	2018-03-08	Otsuka Pharma Co Ltd	(مشتقات 2'-دايوكسي-ريبوفيورانوسيل) 1 , 3 , 4, 7- تترا هيدرو- (1, 3) داي آزيبين- 2 - أون لعلاج السرطان
US8609631B2 (en)	2009-04-06	2013-12-17	Eisai Inc.	Compositions and methods for treating cancer
AU2010234562B2 (en) *	2009-04-06	2016-05-12	Otsuka Pharmaceutical Co., Ltd.	Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
GB0907551D0 (en)	2009-05-01	2009-06-10	Univ Dundee	Treatment or prophylaxis of proliferative conditions
US8618076B2 (en)	2009-05-20	2013-12-31	Gilead Pharmasset Llc	Nucleoside phosphoramidates
TWI583692B (zh)	2009-05-20	2017-05-21	基利法瑪席特有限責任公司	核苷磷醯胺
PL3290428T3 (pl)	2010-03-31	2022-02-07	Gilead Pharmasset Llc	Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
HUE034239T2 (en)	2010-03-31	2018-02-28	Gilead Pharmasset Llc	Method for Crystallization of (S) -isopropyl 2 - (((S) (perfluorophenoxy) (phenoxy) phosphoryl) amino) propanoate \ t
EP2646453A1 (en)	2010-11-30	2013-10-09	Gilead Pharmasset LLC	Compounds
DE202012013074U1 (de)	2011-09-16	2014-10-29	Gilead Pharmasset Lcc	Zusammensetzungen zur Behandlung von HCV
US8889159B2 (en)	2011-11-29	2014-11-18	Gilead Pharmasset Llc	Compositions and methods for treating hepatitis C virus
SG10201706949VA (en)	2013-01-31	2017-09-28	Gilead Pharmasset Llc	Combination formulation of two antiviral compounds
EP4005560A1 (en)	2013-08-27	2022-06-01	Gilead Pharmasset LLC	Combination formulation of two antiviral compounds
MX363205B (es) *	2013-10-29	2019-03-13	Otsuka Pharma Co Ltd	Ruta sintetica para obtener 2'-deoxi-2',2'-difluorotetrahidrouridi nas.
WO2015154064A2 (en)	2014-04-04	2015-10-08	Del Mar Pharmaceuticals	Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
PT3182996T (pt)	2014-08-22	2023-03-21	Celgene Corp	Métodos de tratamento de mieloma múltiplo com compostos imunomoduladores em combinação com anticorpos
BR112018011324A2 (pt)	2015-12-03	2018-12-04	Epidestiny Inc	?composições contendo decitabina, 5azacitidina e tetra-hidrouridina e usos das mesmas?
WO2017158396A1 (en) *	2016-03-16	2017-09-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Cytidine deaminase inhibitors for the treatment of pancreatic cancer
EP3746134A1 (en)	2018-02-02	2020-12-09	Maverix Oncology, Inc.	Small molecule drug conjugates of gemcitabine monophosphate
US11224610B2 (en) *	2018-09-19	2022-01-18	Otsuka Pharmaceutical Co., Ltd.	Low dose combination CDA substrate drug/cedazuridine with extended administration
US20210388361A1 (en) *	2018-10-19	2021-12-16	Interoligo Corporation	Modified nucleic acid having improved treatment efficacy, and anticancer pharmaceutical composition containing same
MX2022004271A (es) *	2019-10-08	2022-06-09	Otsuka Pharma Co Ltd	2'-desoxi-2',2'-difluoro tetrahidruridina de alta pureza y metodos para su preparacion.
IL294288A (en) *	2020-02-25	2022-08-01	Otsuka Pharma Co Ltd	Solid oral dosage forms in combination with decitabine and cadazuridine
BR112023019182A2 (pt) *	2021-03-26	2023-11-28	Cleveland Clinic Found	Uso de um inibidor de citidina desaminase na preparação de um medicamento, sistema, kit ou artigo de manufatura e composição
WO2022254457A1 (en) *	2021-05-29	2022-12-08	Msn Laboratories Private Limited, R&D Center	An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds
WO2023069529A1 (en)	2021-10-19	2023-04-27	Akirabio, Inc.	Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
WO2023076332A1 (en) *	2021-11-01	2023-05-04	St. John's University	Injectable liquid pharmaceutical compostion containing gemcitabine and a cytidine deaminase inhibitor
US20230271996A1 (en) *	2021-12-25	2023-08-31	Scinopharm Taiwan, Ltd.	Process for preparing cedazuridine
WO2024047394A1 (en)	2022-08-31	2024-03-07	Otsuka Pharmaceutical Co., Ltd.	Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4017606A (en) *	1973-10-04	1977-04-12	The Upjohn Company	Organic compounds and process
US4210638A (en) *	1978-03-17	1980-07-01	Pcr, Inc.	Antiviral composition and method of treating virus diseases
US4275057A (en)	1980-01-28	1981-06-23	The United States Of America As Represented By The Department Of Health, Education And Welfare	Seven-membered ring compounds as inhibitors of cytidine deaminase
US4526988A (en)	1983-03-10	1985-07-02	Eli Lilly And Company	Difluoro antivirals and intermediate therefor
AU583801B2 (en)	1983-10-26	1989-05-11	Sheldon B. Greer	Method and materials for sensitizing neoplastic tissue to radiation
EP0184365B1 (en) *	1984-12-04	1993-08-04	Eli Lilly And Company	Improvements in the treatment of tumors in mammals
US5223608A (en) *	1987-08-28	1993-06-29	Eli Lilly And Company	Process for and intermediates of 2',2'-difluoronucleosides
US4965374A (en) *	1987-08-28	1990-10-23	Eli Lilly And Company	Process for and intermediates of 2',2'-difluoronucleosides
US5968914A (en) *	1987-10-28	1999-10-19	Pro-Neuron, Inc.	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1992018517A1 (en)	1991-04-17	1992-10-29	Yale University	Method of treating or preventing hepatitis b virus
EP0543976A4 (en)	1991-04-23	1993-11-10	Oglevee, Ltd.	In vitro leaf petiole multiplication of pelargoniums
FR2682112B1 (fr) *	1991-10-08	1993-12-10	Commissariat A Energie Atomique	Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5606048A (en) *	1992-06-22	1997-02-25	Eli Lilly And Company	Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5821357A (en) *	1992-06-22	1998-10-13	Eli Lilly And Company	Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
US5426183A (en) *	1992-06-22	1995-06-20	Eli Lilly And Company	Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5594124A (en) *	1992-06-22	1997-01-14	Eli Lilly And Company	Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
US5371210A (en) *	1992-06-22	1994-12-06	Eli Lilly And Company	Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
DE69403588T2 (de) *	1993-02-23	1998-01-22	Hope City	4-ethoxy-5-fluor-2'-deoxyuridine
WO1994026761A1 (en) *	1993-05-14	1994-11-24	Pro-Neuron, Inc.	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) *	1993-06-01	1993-07-21	Hafslund Nycomed As	Cell growth regualtors
US5637688A (en) *	1994-12-13	1997-06-10	Eli Lilly And Company	Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) *	1995-01-18	1996-05-28	Eli Lilly And Company	2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
WO1996026743A1 (en) *	1995-03-01	1996-09-06	Human Gene Therapy Research Institute	Radiation enhanced gene therapy for treatment of tumors
US6001994A (en) *	1995-12-13	1999-12-14	Eli Lilly And Company	Process for making gemcitabine hydrochloride
US5760208A (en) *	1996-08-14	1998-06-02	The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations	Process to prepare pyrimidine nucleosides
US6933287B1 (en) *	1999-03-01	2005-08-23	Sheldon B. Greer	Dramatic simplification of a method to treat neoplastic disease by radiation
AU3354500A (en) *	1999-03-01	2000-09-21	Halogenetics, Inc.	Dramatic simplification of a method to treat neoplastic disease by radiation
AU7018800A (en)	1999-08-26	2001-03-19	Omega Critical Care Limited	Improvements relating to catheter positioning
US6462191B1 (en)	2000-07-13	2002-10-08	Air Products And Chemicals, Inc.	Synthesis of 2-deoxy-2-fluoro-arabinose derivatives
CN102241720B (zh) *	2000-11-29	2014-01-29	三井化学株式会社	L-核酸衍生物及其合成方法
ES2236481T3 (es) *	2001-01-16	2005-07-16	Glaxo Group Limited	Combinacion farmaceutica que contiene una 4-quinazolinamina y paclitaxel, carboplatino o vinorelbina para el tratamiento de cancer.
AU2002257446A1 (en)	2001-05-18	2002-12-03	Rakesh Kumar	Antiviral nucleosides
US8207142B2 (en) *	2001-07-31	2012-06-26	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Inhibitor of DNA methylation
CA2476279A1 (en)	2002-02-14	2003-08-21	Lieven J. Stuyver	Modified fluorinated nucleoside analogues
US6982253B2 (en)	2002-06-05	2006-01-03	Supergen, Inc.	Liquid formulation of decitabine and use of the same
AU2003278904A1 (en)	2002-09-24	2004-04-19	Kornis Pharmaceuticals, Incorporated	1, 3, 5-triazines for treatment of viral diseases
WO2004041203A2 (en)	2002-11-04	2004-05-21	Xenoport, Inc.	Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
WO2005115410A2 (en) *	2004-05-06	2005-12-08	University Of Rochester	Context dependent inhibitors of cytidine deaminases and uses thereof
US20060014949A1 (en)	2004-07-13	2006-01-19	Supergen Inc.	Compositions and formulations of decitabine polymorphs and methods of use thereof
WO2006015346A1 (en)	2004-07-30	2006-02-09	Pharmaessentia Corp.	STEREOSELECTIVE SYNTHESIS OF β-NUCLEOSIDES
TW200634022A (en)	2004-12-08	2006-10-01	Sicor Inc	Difluoronucleosides and process for preparation thereof
WO2008085611A2 (en) *	2006-11-27	2008-07-17	University Of Miami	Designer theraphy of pancreatic tumors
WO2009021551A1 (en)	2007-08-13	2009-02-19	Universite De La Mediterranee	A method for assessing the risk of toxicity in a chemotherapy
JO2778B1 (en) *	2007-10-16	2014-03-15	ايساي انك	Certain vehicles, installations and methods
WO2010047698A1 (en)	2008-10-22	2010-04-29	University Of Alabama At Birmingham	Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases
JO3197B1 (ar) *	2009-04-06	2018-03-08	Otsuka Pharma Co Ltd	(مشتقات 2'-دايوكسي-ريبوفيورانوسيل) 1 , 3 , 4, 7- تترا هيدرو- (1, 3) داي آزيبين- 2 - أون لعلاج السرطان
AU2010234562B2 (en) *	2009-04-06	2016-05-12	Otsuka Pharmaceutical Co., Ltd.	Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
ES2628580T3 (es) *	2009-04-06	2017-08-03	Otsuka Pharmaceutical Co., Ltd.	Combinación de decitabina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer el tratamiento de cáncer
US8609631B2 (en)	2009-04-06	2013-12-17	Eisai Inc.	Compositions and methods for treating cancer

2008
- 2008-10-14 JO JO2008459A patent/JO2778B1/en active
- 2008-10-15 TW TW097139594A patent/TWI445539B/zh active
- 2008-10-16 MY MYPI2010001528A patent/MY147970A/en unknown
- 2008-10-16 ES ES08840633T patent/ES2384011T3/es active Active
- 2008-10-16 WO PCT/US2008/080163 patent/WO2009052287A1/en active Application Filing
- 2008-10-16 EA EA201000642A patent/EA018757B1/ru unknown
- 2008-10-16 ES ES12151552.2T patent/ES2616566T3/es active Active
- 2008-10-16 JP JP2010530110A patent/JP5496899B2/ja active Active
- 2008-10-16 PL PL08840633T patent/PL2207786T3/pl unknown
- 2008-10-16 PT PT08840633T patent/PT2207786E/pt unknown
- 2008-10-16 BR BRPI0818672A patent/BRPI0818672B8/pt active IP Right Grant
- 2008-10-16 AT AT08840633T patent/ATE548374T1/de active
- 2008-10-16 EP EP12151552.2A patent/EP2447272B1/en active Active
- 2008-10-16 UA UAA201003977A patent/UA99476C2/ru unknown
- 2008-10-16 DK DK08840633.5T patent/DK2207786T3/da active
- 2008-10-16 RS RS20120232A patent/RS52323B/en unknown
- 2008-10-16 ME MEP-2010-68A patent/ME00997B/me unknown
- 2008-10-16 US US12/252,961 patent/US8268800B2/en active Active
- 2008-10-16 MX MX2010004109A patent/MX2010004109A/es active IP Right Grant
- 2008-10-16 KR KR1020107010621A patent/KR101543049B1/ko active IP Right Grant
- 2008-10-16 NZ NZ584229A patent/NZ584229A/en unknown
- 2008-10-16 EP EP08840633A patent/EP2207786B1/en active Active
- 2008-10-16 CN CN2008801117195A patent/CN101827856B/zh active Active
- 2008-10-16 CA CA2702274A patent/CA2702274C/en active Active
- 2008-10-16 SI SI200830624T patent/SI2207786T1/sl unknown
- 2008-10-18 SA SA08290661A patent/SA08290661B1/ar unknown
2010
- 2010-01-26 ZA ZA2010/02178A patent/ZA201002178B/en unknown
- 2010-03-25 IL IL204732A patent/IL204732A/en active IP Right Grant
- 2010-04-09 EC EC2010010095A patent/ECSP10010095A/es unknown
- 2010-04-12 GT GT201000088A patent/GT201000088A/es unknown
- 2010-04-14 NI NI201000055A patent/NI201000055A/es unknown
- 2010-05-12 CR CR11427A patent/CR11427A/es unknown
- 2010-05-13 CO CO10057462A patent/CO6270330A2/es active IP Right Grant
2011
- 2011-01-20 HK HK11100565.2A patent/HK1146410A1/xx unknown
2012
- 2012-05-16 HR HRP20120419AT patent/HRP20120419T1/hr unknown
- 2012-05-24 CY CY20121100467T patent/CY1112781T1/el unknown
- 2012-07-24 US US13/556,404 patent/US8618075B2/en active Active
2013
- 2013-11-25 US US14/088,465 patent/US8951987B2/en active Active
2014
- 2014-03-05 JP JP2014043175A patent/JP5859588B2/ja active Active
- 2014-12-29 US US14/584,437 patent/US9567363B2/en active Active
2023
- 2023-12-21 HU HUS2300044C patent/HUS2300044I1/hu unknown
- 2023-12-21 NO NO2023048C patent/NO2023048I1/no unknown
- 2023-12-21 HU HUS2300045C patent/HUS2300045I1/hu unknown
- 2023-12-21 NO NO2023047C patent/NO2023047I1/no unknown
- 2023-12-22 FI FIC20230040C patent/FIC20230040I1/fi unknown
- 2023-12-22 FI FIC20230039C patent/FIC20230039I1/fi unknown
- 2023-12-26 FR FR23C1051C patent/FR23C1051I1/fr active Active
- 2023-12-26 FR FR23C1052C patent/FR23C1052I1/fr active Active
- 2023-12-27 NL NL301256C patent/NL301256I2/nl unknown

Also Published As

Publication number	Publication date
TW200924786A (en)	2009-06-16
EA018757B1 (ru)	2013-10-30
CA2702274A1 (en)	2009-04-23
CO6270330A2 (es)	2011-04-20
US9567363B2 (en)	2017-02-14
EP2207786B1 (en)	2012-03-07
HK1146410A1 (en)	2011-06-03
RS52323B (en)	2012-12-31
EA201000642A1 (ru)	2010-10-29
AU2008312435B2 (en)	2014-04-17
ECSP10010095A (es)	2010-07-30
KR101543049B1 (ko)	2015-08-07
US20150210730A1 (en)	2015-07-30
TWI445539B (zh)	2014-07-21
FIC20230040I1 (fi)	2023-12-22
JP2014177455A (ja)	2014-09-25
CN101827856B (zh)	2013-02-06
WO2009052287A1 (en)	2009-04-23
IL204732A (en)	2013-07-31
HUS2300044I1 (hu)	2024-01-28
MX2010004109A (es)	2010-08-10
ZA201002178B (en)	2011-05-25
JO2778B1 (en)	2014-03-15
NI201000055A (es)	2010-08-13
PT2207786E (pt)	2012-05-28
US8951987B2 (en)	2015-02-10
GT201000088A (es)	2012-03-13
KR20100091978A (ko)	2010-08-19
US20090137521A1 (en)	2009-05-28
MY147970A (en)	2013-02-28
HRP20120419T1 (hr)	2012-07-31
NL301256I1 (nl)	2024-01-03
US8618075B2 (en)	2013-12-31
US20140186335A1 (en)	2014-07-03
BRPI0818672B1 (pt)	2020-10-20
FR23C1052I1 (fr)	2024-01-26
BRPI0818672B8 (pt)	2021-05-25
NO2023047I1 (no)	2023-12-21
BRPI0818672A2 (pt)	2015-04-14
ATE548374T1 (de)	2012-03-15
AU2008312435A8 (en)	2014-07-24
ES2384011T3 (es)	2012-06-28
NO2023048I1 (en)	2023-12-21
SA08290661B1 (ar)	2012-06-10
ES2616566T3 (es)	2017-06-13
EP2447272B1 (en)	2017-02-01
US8268800B2 (en)	2012-09-18
JP2011500713A (ja)	2011-01-06
JP5859588B2 (ja)	2016-02-10
UA99476C2 (en)	2012-08-27
DK2207786T3 (da)	2012-06-18
IL204732A0 (en)	2010-11-30
CA2702274C (en)	2015-12-29
FR23C1051I1 (fr)	2024-01-26
CN101827856A (zh)	2010-09-08
EP2447272A1 (en)	2012-05-02
JP5496899B2 (ja)	2014-05-21
FIC20230039I1 (fi)	2023-12-22
ME00997B (me)	2012-10-20
CY1112781T1 (el)	2016-02-10
CR11427A (es)	2010-08-16
NZ584229A (en)	2012-06-29
SI2207786T1 (sl)	2012-10-30
EP2207786A1 (en)	2010-07-21
AU2008312435A1 (en)	2009-04-23
HUS2300045I1 (hu)	2024-01-28
US20120289475A1 (en)	2012-11-15
PL2207786T3 (pl)	2012-09-28

Publication	Publication Date	Title
NL301256I2 (nl)	2024-01-11	cedazuridine, of een farmaceutisch aanvaardbaar zout daarvan
NL301166I2 (nl)	2022-07-06	Avacopan of een farmaceutisch aanvaardbaar zout daarvan
NL301071I2 (nl)	2020-12-01	alpelisib of een farmaceutisch aanvaardbaar zout ervan
NL301209I2 (nl)	2023-01-24	capmatinib of een farmaceutisch aanvaardbaar zout daarvan
NL300886I2 (nl)	2017-10-24	baricitinib, of een farmaceutisch aanvaardbaar zout daarvan
NL301003I2 (nl)	2019-10-29	Sotagliflozin of een farmaceutisch aanvaardbaar zout daarvan
NL300993I2 (nl)	2019-07-11	Apalutamide of een farmaceutisch aanvaardbaar zout daarvan
NL301250I2 (nl)	2023-11-23	piflufolastat (18F) of een farmaceutisch aanvaardbaar zout daarvan
NL301106I2 (nl)	2021-08-03	Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan
NL300990I1 (nl)	2019-05-29	Brigatinib, dan wel een farmaceutisch aanvaardbaar zout daarvan
NL301035I2 (nl)	2020-04-15	upadacitinib of een farmaceutisch aanvaardbaar zout daarvan
NL301187I2 (nl)	2022-08-04	Rimegepant of een farmaceutisch aanvaardbaar zout daarvan
NO2020038I1 (no)	2020-11-18	Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt
NL301202I1 (nl)	2022-11-09	Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline
NL301065I2 (nl)	2020-10-28	Ozanimod of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder ozanimodhydrochloride
NL301021I2 (nl)	2020-04-14	talazoparib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
NL301150I2 (nl)	2022-11-24	setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301049I1 (nl)	2020-07-01	Crisaborale, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301157I2 (nl)	2023-11-09	odevixibat of een farmaceutisch aanvaardbaar zout daarvan
NL301067I2 (nl)	2020-10-28	Cefiderocol, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat
NL300909I2 (nl)	2017-12-19	Ribociclib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NO2016016I1 (no)	2016-08-17	Lesinurad, eller et farmasøytisk akseptabelt salt derav
NL300971I2 (nl)	2019-04-11	Eravacycline, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL300901I2 (nl)	2017-11-16	pibrentasvir of een farmaceutisch aanvaardbaar zout daarvan
NL301248I2 (nl)	2023-11-20	atogepant of een farmaceutisch aanvaardbaar zout daarvan